Kevin Latinis
Rheumatology · Leawood, KSNPI 1699878686
Payments from drug & device makers
Across 783 payments — averaging $27.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$6K
- Sanofi$2K
- Amgen$2K
- AbbVie$2K
- UCB, Inc.$2K
- Novartis$1K
- plus $6K from 36 others
What the payments were for
- Consulting fees$7,80536%
- Travel & lodging$7283%
- Food & beverage$12,68459%
- Education$1781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORENCIA$5,049
- KEVZARA$2,110
- PURIFIED CORTROPHIN GEL$386
- ACTHAR$122
How this compares
$21,396 in reported general payments places this provider in the 80th percentile of 49 rheumatology providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 99 | $819,575 |
| Humira(Cf) PenAdalimumab | 96 | $689,997 |
| Skyrizi PenRisankizumab-Rzaa | 23 | $525,978 |
| TremfyaGuselkumab | 18 | $250,255 |
| Xeljanz XrTofacitinib Citrate | 38 | $233,133 |
| BenlystaBelimumab | 30 | $143,264 |
| Cimzia (2 Pack)Certolizumab Pegol | 18 | $113,397 |
| Humira(Cf)Adalimumab | 13 | $104,524 |
| Taltz AutoinjectorIxekizumab | 12 | $81,119 |
| XeljanzTofacitinib Citrate | 14 | $78,018 |
| OtezlaApremilast | 15 | $70,501 |
| Fentanyl | 138 | $21,487 |
| Hydroxychloroquine Sulfate | 333 | $13,993 |
| Teriparatide | 13 | $13,005 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 481 | $11,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $1,998 | $924,099112 claims |
| Johnson & JohnsonTremfya | $995 | $250,25518 claims |
| GSKBenlysta, Arexvy | $614 | $146,42341 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,742 | $113,39718 claims |
| PfizerXeljanz, Lyrica | $1,018 | $88,05125 claims |
| AmgenOtezla | $2,389 | $70,50115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 49 rheumatology providers in Kansas.
Other rheumatology in Leawood
- Jonathan KatzLeawood$243
- Shadi ShahouriWichita$635K
- Basit MalikHutchinson$186K
- Paul SchmidtKansas City$143K
- James AndersonOverland Park$75K
- Shashank RadadiyaKansas City$74K
- Timothy ShaverWichita$39K
- Stephen RuhlmanOverland Park$32K
- Arnold KatzOverland Park$25K
- Aruna BarathamOverland Park$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.